учебник по английскому афанасьева 5 класс 2 часть
Главное меню:
Интересное
учебник по английскому афанасьева 5 класс 2 часть, Efficacy and Safety of Biologics for Chronic Rhinosinusitis , Biological therapy in chronic rhinosinusitis with nasal polyps, Ultra-long-acting biological therapy for chronic - The Lancet, Biologics for Chronic Rhinosinusitis With Nasal Polyps , Tezspire for Nasal Polyps: A New Targeted Therapy on the , , .
Dupilumab, omalizumab, mepolizumab, and benralizumab have demonstrated good efficacy and safety in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP) in phase 3 randomised controlled trials (RCTs). With recent regulatory approvals, there has been a surge in real-world studies (RWSs). This systematic review and meta-analysis aimed to summarise the efficacy and safety of these four biologics in real-world settings. Primary outcomes were nasal polyp score and sino-nasal outcome test-22 score. Secondary outcomes included smell identification test score, loss of smell score, nasal congestion score, overall nasal symptom score, treatment response, and adverse events (AEs) prompting discontinuation. Efficacy outcomes at 4, 6, 12, and over 12 months were summarised, and meta-analyses of mean changes from baseline were conducted. Sixty-four RWSs involving 3921 patients were included. Significant improvements in clinical outcomes were observed at most follow-up time points, with dupilumab showing particularly notable effects. The efficacy observed in these RWSs was superior to that demonstrated in phase 3 RCTs. All biologics exhibited low discontinuation rates due to AEs. Overall, biologic treatments for CRSwNP in real-world settings demonstrate strong efficacy and good safety. However, the limitations in current RWSs highlight the need for long-term, high-quality multicentre prospective studies and comprehensive healthcare database analyses., Dupilumab, omalizumab, mepolizumab, and benralizumab have demonstrated good efficacy and safety in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP) in phase 3 randomised controlled trials (RCTs). With recent regulatory approvals, there has been a surge in real-w …, Expert opinion . In recent years, biological therapy has been in the spotlight in clinical studies on CRSwNP. Biologics have proven to be efficacious in reducing nasal polyp size, alleviating CRSwNP-related symptoms, improving quality of life, and reducing the need for systemic corticosteroids or endoscopic sinus surgery for nasal polyps..
Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a common and particularly severe subset of sinonasal inflammatory disease that is characterised by benign outgrowths of the inflamed mucosa. The management framework of CRSwNP substantially shifted with the introduction of biological agents.1–3 These therapies, targeting the Th2 cell cytokine pathways, drove reductions in both systemic , The study revealed that 86.4% of respondents had prescribed biologics, with dupilumab as the preferred choice (71.1%). The primary indication for biologic use was recurrent nasal polyps after surgery (87.2%). However, high cost (48.6%) was the most common reason for discontinuation., June 17, 2025. Tezspire for Nasal Polyps: A New Targeted Therapy on the Horizon. June 17, 2025. Anaphylm: The Needle-Free Epinephrine. June 4, 2025. FDA Warning: Stopping Zyrtec or Xyzal May Cause Rebound Itching—What Allergy Patients Need to Know. June 3, 2025. How the Palisades and Altadena Fires Are Affecting Your Sinuses, Lungs, and Long , , , .